July 2015

Patients in practices where certified diabetes educators were embedded in practices were more likely to have medication adjusted quickly, with better health outcomes.

Natasha Greene, PhD, FNP, BC, found that educating a family member alongside the person with type 2 diabetes mellitus produced better health outcomes than traditional education.

The study presented at the ADA Scientific Sessions found that raising out-of-pocket costs for diabetics with Medicare could reduce adherence and ultimately raise healthcare spending.

An overview of mechanism of action, dosing, interactions, and precautions for evolocumab, which faces an FDA deadline for review August 27, 2015.

The shift in care for those with diabetes is about new payment models and a change in mindset, said the speakers, including Robert A. Gabbay, MD, PhD, of Joslin Diabetes Center.

A matchstick-like device provides continuous delivery of exenatide, producing dramatic reductions in A1C levels.

The sessions offered a backgroup to announced new partnerships and reveal new technology.

The study evaluated the 3 new anti-VEGF agents for treatment of a condition that frequently occurs in patients who suffer from diabetes mellitus.

A review published before FDA's vote on alirocumab outlines how editorials in 2 major journals were reflected in subsequent votes by advisory panels.

The need for spirometry before physicians can write an Afrezza prescription has been cited by analysts as an impediment to broader use of the inhaled insulin.

The CDC has found that some digital programs meet standards required to help payers deliver behavioral health programs for persons with obesity, or those who are overweight with at least 1 cardiovascular risk factor.

Data from mHealth can inform, assess, anticipate, and aid in interventions while monitoring and coordinating patient health status and care.

On the eve of FDA's deadline for acting on the first of an expensive new class of cholesterol therapies, the chief medical officer of the nation's largest pharmacy benefit manager weighs on what steps it is taking on behalf of customers in this changing landscape.

A leading voice on diabetes care asks why Medicare still will not cover CGM technology.

Years of work has moved technology to the point of large-scale testing that is required before FDA approval and commercialization.